Trial Profile

A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NB 001 (Primary)
Indications DiGeorge syndrome
Focus Adverse reactions
Sponsors Nobias Therapeutics

Most Recent Events

05 Oct 2023 Status changed from active, no longer recruiting to completed.
30 Mar 2023 Planned End Date changed from 26 May 2023 to 29 May 2023.
30 Mar 2023 Planned primary completion date changed from 28 Apr 2023 to 1 May 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com